Cellebrite DI Ltd. - Ordinary Shares (NQ:CLBT)Price and VolumeDetailed Quote
Top NewsMore NewsPerformance
52-Week Range
45.1% below 52-week high
10.65
9.5852W Low
19.3952W High
1 Week
22.0% below 1-week high
10.431W Low
13.651W High
Cellebrite DI Ltd. - Ordinary Shares (CLBT) traded between $9.58 and $19.39 over the past 52 weeks and last traded at $10.65, 45.1% below its 52-week high. Over the past week it ranged between $10.43 and $13.65.
Past 12 Months
1W
-$2.05
1M
-$0.49
3M
-$0.35
6M
-$2.81
YTD
-$7.19
1Y
-$7.52
CLBT was -41.4% over the past year, -20.9% over six months, -40.3% year to date, -16.1% in the last week.
12 Months vs Market
CLBT
DIA
SPY
QQQ
IWM
Over the past 12 months CLBT returned -41.4% versus DIA (Dow) +8.8%, SPY (S&P 500) +10.0%, QQQ (Nasdaq 100) +8.8% and IWM (Russell 2000) +15.6%.
Volume & Liquidity
0.00× 3-mo avg
Today 115
3-mo avg 2.5M
1W
1M
3M
6M
YTD
1Y
CLBT most recently traded 115 shares against a 3-month average daily volume of 2.5M. More NewsRead More
Cellebrite (CLBT) Q3 2026 Earnings Call Transcript ↗
November 12, 2026
Cellebrite DI Q3 Earnings Call Highlights ↗
November 12, 2026
Frequently Asked QuestionsIs Cellebrite DI Ltd. - Ordinary Shares publicly traded?
Yes, Cellebrite DI Ltd. - Ordinary Shares is publicly traded.
What exchange does Cellebrite DI Ltd. - Ordinary Shares trade on?
Cellebrite DI Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Cellebrite DI Ltd. - Ordinary Shares?
The ticker symbol for Cellebrite DI Ltd. - Ordinary Shares is CLBT on the Nasdaq Stock Market
What is the current price of Cellebrite DI Ltd. - Ordinary Shares?
The current price of Cellebrite DI Ltd. - Ordinary Shares is 10.65
When was Cellebrite DI Ltd. - Ordinary Shares last traded?
The last trade of Cellebrite DI Ltd. - Ordinary Shares was at 11/17/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
| ||||||||||||||||||||||||